The Combined Contraceptive Vaginal Ring (NuvaRing): Evaluation of the Clinical and Pharmacological Evidence

Abstract

The NuvaRing® is a vaginal ring contraceptive that releases a daily dose of 15 μg ethinylestradiol and 120 μg etonogestrel through the vaginal epithelium, thereby avoiding the daily fluctuations in serum levels typically observed with combined oral contraceptives. Each ring is designed for a single 3-week use followed by a 1-week ring-free period. The ring offers robust inhibition of ovulation, yielding a Pearl Index of 0.65 for European women in registration trials. The ring has the same contraindications as combined oral contraceptives. The vaginal ring is a highly effective, safe and well-tolerated method of hormonal contraception designed for reproductive-aged women who desire freedom from the daily pill.